Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 128

1.

Prospects for treatment of pediatric vitreoretinal diseases with vascular endothelial growth factor inhibition.

Lin KL, Hirose T, Kroll AJ, Lou PL, Ryan EA.

Semin Ophthalmol. 2009 Mar-Apr;24(2):70-6. doi: 10.1080/08820530902800108. Review.

PMID:
19373689
[PubMed - indexed for MEDLINE]
2.

Intravitreal and intracameral bevacizumab to treat neovascular complications of retinopathy of prematurity.

dell'Omo R, Kulkarni A, Franks WA.

Acta Ophthalmol. 2008 Sep;86(6):698-700. No abstract available.

PMID:
18081905
[PubMed - indexed for MEDLINE]
3.

Elevated vascular endothelial growth factor level in Coats' disease and possible therapeutic role of bevacizumab.

He YG, Wang H, Zhao B, Lee J, Bahl D, McCluskey J.

Graefes Arch Clin Exp Ophthalmol. 2010 Oct;248(10):1519-21. doi: 10.1007/s00417-010-1366-1. Epub 2010 Apr 9.

PMID:
20379736
[PubMed - indexed for MEDLINE]
4.

Anti-vascular endothelial growth factor therapy for ocular neovascular disease.

Andreoli CM, Miller JW.

Curr Opin Ophthalmol. 2007 Nov;18(6):502-8. Review.

PMID:
18163003
[PubMed - indexed for MEDLINE]
5.

Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity.

Kychenthal A, Dorta P.

Retina. 2010 Apr;30(4 Suppl):S32-6. doi: 10.1097/IAE.0b013e3181ca146b.

PMID:
20224474
[PubMed - indexed for MEDLINE]
6.

Rapid regression of retinal hemorrhage and neovascularization in a case of familial exudative vitreoretinopathy treated with intravitreal bevacizumab.

Tagami M, Kusuhara S, Honda S, Tsukahara Y, Negi A.

Graefes Arch Clin Exp Ophthalmol. 2008 Dec;246(12):1787-9. doi: 10.1007/s00417-008-0949-6. Epub 2008 Sep 16.

PMID:
18795314
[PubMed - indexed for MEDLINE]
7.

Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction.

Ramasubramanian A, Shields CL.

Br J Ophthalmol. 2012 Mar;96(3):356-9. doi: 10.1136/bjophthalmol-2011-300141. Epub 2011 Jun 7.

PMID:
21653215
[PubMed - indexed for MEDLINE]
8.

Anti-angiogenic therapy in the management of retinopathy of prematurity.

Drenser KA.

Dev Ophthalmol. 2009;44:89-97. doi: 10.1159/000223949. Epub 2009 Jun 3. Review.

PMID:
19494656
[PubMed - indexed for MEDLINE]
9.

Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study.

Kong L, Mintz-Hittner HA, Penland RL, Kretzer FL, Chévez-Barrios P.

Arch Ophthalmol. 2008 Aug;126(8):1161-3. doi: 10.1001/archophthalmol.2008.1. No abstract available.

PMID:
18695118
[PubMed - indexed for MEDLINE]
10.

[Molecular pathogenesis of ocular vascular disease--anti-angiogenesis as a therapeutic concept].

Joussen AM.

Dtsch Med Wochenschr. 2007 Jun 8;132(23):1268-72. Review. German.

PMID:
17541869
[PubMed - indexed for MEDLINE]
11.

Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity.

Honda S, Hirabayashi H, Tsukahara Y, Negi A.

Graefes Arch Clin Exp Ophthalmol. 2008 Jul;246(7):1061-3. doi: 10.1007/s00417-008-0786-7. Epub 2008 Mar 5.

PMID:
18320201
[PubMed - indexed for MEDLINE]
12.

Antivascular endothelial growth factor for retinopathy of prematurity.

Mintz-Hittner HA, Best LM.

Curr Opin Pediatr. 2009 Apr;21(2):182-7. doi: 10.1097/MOP.0b013e32832925f9. Review.

PMID:
19300261
[PubMed - indexed for MEDLINE]
13.

Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity.

Zepeda-Romero LC, Liera-Garcia JA, Gutiérrez-Padilla JA, Valtierra-Santiago CI, Avila-Gómez CD.

Eye (Lond). 2010 May;24(5):931-3. doi: 10.1038/eye.2009.156. Epub 2009 Jun 26. No abstract available. Erratum in: Eye (Lond). 2010 Jan;24(1):202. Cardenas-Lamas, L J [corrected to Avila-Gómez, C D].

PMID:
19557020
[PubMed - indexed for MEDLINE]
14.

The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.

Stewart MW.

Mayo Clin Proc. 2012 Jan;87(1):77-88. doi: 10.1016/j.mayocp.2011.10.001. Review.

PMID:
22212972
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity.

Travassos A, Teixeira S, Ferreira P, Regadas I, Travassos AS, Esperancinha FE, Prieto I, Pires G, van Velze R, Valido A, Machado Mdo C.

Ophthalmic Surg Lasers Imaging. 2007 May-Jun;38(3):233-7.

PMID:
17552391
[PubMed - indexed for MEDLINE]
16.
17.

[Pharmacological treatment for retinopathy of prematurity].

Stahl A, Agostini H, Jandeck C, Lagrèze W.

Ophthalmologe. 2011 Aug;108(8):777-85; quiz 786-7. doi: 10.1007/s00347-011-2371-4. German.

PMID:
21853221
[PubMed - indexed for MEDLINE]
18.

Current molecular understanding and future treatment strategies for pathologic ocular neovascularization.

Tolentino MJ.

Curr Mol Med. 2009 Nov;9(8):973-81. Review.

PMID:
19925410
[PubMed - indexed for MEDLINE]
19.

Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels.

Lee JY, Chae JB, Yang SJ, Yoon YH, Kim JG.

Graefes Arch Clin Exp Ophthalmol. 2010 Sep;248(9):1257-62. doi: 10.1007/s00417-010-1375-0.

PMID:
20393741
[PubMed - indexed for MEDLINE]
20.

Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned?

Lim LS, Cheung CM, Mitchell P, Wong TY.

Am J Ophthalmol. 2011 Sep;152(3):329-31. doi: 10.1016/j.ajo.2011.05.040. No abstract available.

PMID:
21855670
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk